FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381619998> ?p ?o ?g. }

• W4381619998 abstract "Abstract Study question What are the live birth and neonatal outcomes following an individualised follitropin delta dosing regimen in either a long GnRH agonist or GnRH antagonist protocol? Summary answer Live birth rates and neonatal outcomes were similar, supporting the efficacy and safety of follitropin delta in both GnRH agonist and antagonist protocols. What is known already Follitropin delta is used for ovarian stimulation and is administered as a fixed daily dose, individualised based on bodyweight and anti-Müllerian (AMH) levels. Registrational trials for follitropin delta used a GnRH antagonist protocol. Preliminary study data shows that individualized follitropin delta is efficacious when used with a long GnRH agonist protocol (RAINBOW trial); however, there is no comparative data for the effects on live birth rates and neonatal outcomes with individualised follitropin delta in a long GnRH agonist versus an antagonist protocol. Study design, size, duration This RCT compared the efficacy and safety of individualised follitropin delta dosing using a long GnRH agonist versus an antagonist protocol and was conducted between May 2019 and February 2022. The trial was designed to describe potential differences in the number of oocytes retrieved between the two GnRH analogue protocols (reported separately). A total of 437 participants were randomised, with a post-trial follow-up period to 4 weeks after birth to record birth and neonatal outcomes. Participants/materials, setting, methods Participants were 18–40 years old with AMH ≤35 pmol/L, undergoing their first ovarian stimulation cycle for IVF/ICSI at specialist reproductive health clinics in Austria, Denmark, Israel, Italy, the Netherlands, Norway and Switzerland.Live birth rates were compared using a logistic regression model with age and AMH at screening as factors. Multiple imputation was used for randomised subjects withdrawing before start of stimulation. Subjects with transfer cancellation due to COVID-19 related reasons were excluded. Main results and the role of chance All participants had a single blastocyst transferred, except two participants ≥38 years in the agonist group who received a double transfer resulting in one dichorionic diamniotic pregnancy for one subject, complicated by maternal hypertension and preterm birth at 33 weeks. All 133 participants with ongoing pregnancies (138 fetuses) were included in this post-trial follow-up analysis. Late pregnancy losses (after confirmed ongoing pregnancy) were similar in the agonist and antagonist groups (2.7% and 1.7%). There were 130 live births (agonist group: 75 neonates [67 singletons; 4 sets of twins]; antagonist group: 60 neonates [58 singletons; 1 set of twins]). Estimated live-birth rates were 35.8% and 28.7% in the agonist and antagonist groups, respectively, per started cycle (treatment difference 7.15%; 95% CI: –2.02; 16.31; p = 0.1265). There were two neonatal deaths in the agonist group – a set of monochorionic twins born at gestational age 24 weeks + 2 days died shortly after birth due to prematurity. The two treatment groups were comparable with respect to neonatal health data for singletons and twins, and incidence of congenital malformations (2.7% and 3.3%, respectively). Neonatal admissions to intensive care units were similar for both groups (10 and six neonates, respectively). Limitations, reasons for caution Double blastocyst transfer was permitted for participants ≥38 years with no good-quality blastocysts. Neonatal health is dependent on singleton/twin status. Outcomes of transfers with cryopreserved blastocysts were not followed up – the cumulative live birth rates and neonatal outcomes after cryo-transfer are not known. Wider implications of the findings The safety profile of individualised follitropin delta dosing was similar in GnRH agonist and antagonist protocols. Live birth rates following individualised follitropin delta were also similar for both GnRH protocols. There were no safety concerns with respect to the neonatal health after ovarian stimulation with follitropin delta. Trial registration number ClinicalTrials.gov identifier: NCT03809429; EudraCT number: 2017-002783-40" @default.
• W4381619998 created "2023-06-23" @default.
• W4381619998 creator A5007554920 @default.
• W4381619998 creator A5008129850 @default.
• W4381619998 creator A5018391950 @default.
• W4381619998 creator A5035365163 @default.
• W4381619998 creator A5079106999 @default.
• W4381619998 creator A5081396339 @default.
• W4381619998 creator A5085234723 @default.
• W4381619998 creator A5087021385 @default.
• W4381619998 date "2023-06-01" @default.
• W4381619998 modified "2023-09-23" @default.
• W4381619998 title "P-761 Live-birth and neonatal outcomes from BEYOND, a randomised controlled trial comparing efficacy and safety of individualised follitropin delta dosing in GnRH agonist versus antagonist protocols" @default.
• W4381619998 doi "https://doi.org/10.1093/humrep/dead093.1074" @default.
• W4381619998 hasPublicationYear "2023" @default.
• W4381619998 type Work @default.
• W4381619998 citedByCount "0" @default.
• W4381619998 crossrefType "journal-article" @default.
• W4381619998 hasAuthorship W4381619998A5007554920 @default.
• W4381619998 hasAuthorship W4381619998A5008129850 @default.
• W4381619998 hasAuthorship W4381619998A5018391950 @default.
• W4381619998 hasAuthorship W4381619998A5035365163 @default.
• W4381619998 hasAuthorship W4381619998A5079106999 @default.
• W4381619998 hasAuthorship W4381619998A5081396339 @default.
• W4381619998 hasAuthorship W4381619998A5085234723 @default.
• W4381619998 hasAuthorship W4381619998A5087021385 @default.
• W4381619998 hasBestOaLocation W43816199981 @default.
• W4381619998 hasConcept C126322002 @default.
• W4381619998 hasConcept C168563851 @default.
• W4381619998 hasConcept C170493617 @default.
• W4381619998 hasConcept C2777288759 @default.
• W4381619998 hasConcept C2778279030 @default.
• W4381619998 hasConcept C2778575703 @default.
• W4381619998 hasConcept C2778894405 @default.
• W4381619998 hasConcept C2778938600 @default.
• W4381619998 hasConcept C2779234561 @default.
• W4381619998 hasConcept C2781413609 @default.
• W4381619998 hasConcept C29456083 @default.
• W4381619998 hasConcept C54355233 @default.
• W4381619998 hasConcept C71315377 @default.
• W4381619998 hasConcept C71924100 @default.
• W4381619998 hasConcept C86803240 @default.
• W4381619998 hasConceptScore W4381619998C126322002 @default.
• W4381619998 hasConceptScore W4381619998C168563851 @default.
• W4381619998 hasConceptScore W4381619998C170493617 @default.
• W4381619998 hasConceptScore W4381619998C2777288759 @default.
• W4381619998 hasConceptScore W4381619998C2778279030 @default.
• W4381619998 hasConceptScore W4381619998C2778575703 @default.
• W4381619998 hasConceptScore W4381619998C2778894405 @default.
• W4381619998 hasConceptScore W4381619998C2778938600 @default.
• W4381619998 hasConceptScore W4381619998C2779234561 @default.
• W4381619998 hasConceptScore W4381619998C2781413609 @default.
• W4381619998 hasConceptScore W4381619998C29456083 @default.
• W4381619998 hasConceptScore W4381619998C54355233 @default.
• W4381619998 hasConceptScore W4381619998C71315377 @default.
• W4381619998 hasConceptScore W4381619998C71924100 @default.
• W4381619998 hasConceptScore W4381619998C86803240 @default.
• W4381619998 hasIssue "Supplement_1" @default.
• W4381619998 hasLocation W43816199981 @default.
• W4381619998 hasOpenAccess W4381619998 @default.
• W4381619998 hasPrimaryLocation W43816199981 @default.
• W4381619998 hasRelatedWork W2010802573 @default.
• W4381619998 hasRelatedWork W2027913950 @default.
• W4381619998 hasRelatedWork W2028293475 @default.
• W4381619998 hasRelatedWork W2058205365 @default.
• W4381619998 hasRelatedWork W2070611629 @default.
• W4381619998 hasRelatedWork W2370665048 @default.
• W4381619998 hasRelatedWork W3189102023 @default.
• W4381619998 hasRelatedWork W4304013889 @default.
• W4381619998 hasRelatedWork W87889950 @default.
• W4381619998 hasRelatedWork W2186436080 @default.
• W4381619998 hasVolume "38" @default.
• W4381619998 isParatext "false" @default.
• W4381619998 isRetracted "false" @default.
• W4381619998 workType "article" @default.